Clinical Potential of Targeting Bruton's Tyrosine Kinase

REFERENCES

• Leukemia and Lymphoma Society. Leukemia, lymphoma, myeloma facts, 2006–2007, www.leukemia-lymphoma.org Available at
   Google Scholar
• National Cancer Institute. A snapshot of leukemia, http://planning.cancer.gov/disease/snapshots.shtml Available at
   Google Scholar
• National Cancer Institute, http://seer.cancer.gov Available at
   Google Scholar
• National Cancer Institute, www.cancer.gov Leukemia. Available at
   Google Scholar
• National Cancer Institute. American Cancer Society. What are the key statistics about acute lymphoblastic leukemia, www.cancer.org Available at
   Google Scholar
• American Cancer Society. What are the key statistics about chronic lymphocytic leukemia, www.cancer.org Available at
   Google Scholar
• Gaynon P. S. Childhood acute lymphoblastic leukaemia and relapse. Br. J. Haematol. 2005; 131: 579–587
   PubMed Web of Science ®Google Scholar
• Gaynon P., Trigg M., Uckun F. M. Childhood acute lymphoblastic leukemia. Cancer Medicine Fifth ed., James Holland, Emil Frei, Robert Bast. B. C. Decker, OntarioCanada 2000
   Google Scholar
• Pui C. H., Evans W. E. Treatment of acute lymphoblastic leukemia. N. Engl. J. Med. 2006; 354: 166–178
   PubMed Web of Science ®Google Scholar
• Leukemia and Lymphoma Society. Leukemia facts and statistics, http://www.leukemia-lymphoma.org/all_page?item_id=9346 Available at
   Google Scholar
• Uckun F. M., Morar S. Q. Vinorelbine-based salvage chemotherapy for therapy-refractory aggressive leukemias. Br. J. Hematol. 2006; 135: 500–508
   PubMed Web of Science ®Google Scholar
• Chessells J. M., Veys P., Kempski H., Henley P., Leiper A., Webb D., Hann I. M. Long-term follow-up of relapsed childhood acute lymphoblastic leukaemia. Br. J. Haematol., 2003; 123: 396–405
   PubMed Web of Science ®Google Scholar
• Gaynon P. S. Childhood acute lymphoblastic leukaemia and relapse. Br. J. Haematol. 2005; 131: 579–587
   PubMed Web of Science ®Google Scholar
• Uckun F. M., Nachman J. B., Sather H. N., Sensel M. G., Kraft P., Steinherz P. G., Lange B., Hutchinson R., Reaman G. H., Gaynon P. S., et al. Clinical significance of Philadelphia chromosome positive pediatric acute lymphoblastic leukemia in the context of contemporary intensive therapies: a report from the Children's Cancer Group. Cancer, 1998; 83: 2030–2039
   PubMed Web of Science ®Google Scholar
• Vilmer E., Suciu S., Ferster A., Bertrand Y., Cave H., Thyss A., Benoit Y., Dastugue N., Fournier M., Souillet G., et al. Long-term results of three randomized trials (58831, 58832, 58881) in childhood acute lymphoblastic leukemia: a CLCG-EORTC report. Children Leukemia Cooperative Group. Leukemia, 2000; 14: 2257–2266
   PubMed Web of Science ®Google Scholar
• Einsiedel H. G., von Stackelberg A., Hartmann R., Fengler R., Schrappe M., Janka-Schaub G., Mann G., Hahlen K., Gobel U., Klingebiel T., et al. Long-term outcome in children with relapsed ALL by risk-stratified salvage therapy: results of trial acute lymphoblastic leukemia-relapse study of the Berlin-Frankfurt-Munster Group 87. J. Clin. Oncol., 2005; 23: 7942–7950
   PubMed Web of Science ®Google Scholar
• Pui C. H., Evans W. E. Treatment of acute lymphoblastic leukemia. N. Engl. J. Med. 2006; 354: 166–178
   PubMed Web of Science ®Google Scholar
• Nachman J. B., Sather H. N., Sensel M. G., et al. Augmented post-induction therapy for children with high-risk acute lymphoblastic leukemia and a slow response to initial therapy. N. Engl. J. Med. 1998; 338: 1663–1671
   PubMed Web of Science ®Google Scholar
• Gaynon P. S., Trigg M. E., Heerema N. A., et al. Children's Cancer Group trials in childhood acute lymphoblastic leukemia: 1983–1995. Leukemia, 2000; 14: 2223–2233
   PubMed Web of Science ®Google Scholar
• Kamps W. A., Bokkerink J. P., Hakvoort-Cammel F. G., et al. BFM-oriented treatment for children with acute lymphoblastic leukemia without cranial irradiation and treatment reduction for standard risk patients: results of DCLSG protocol ALL-8 (1991–1996). Leukemia, 2002; 16: 1099–1111
   PubMed Web of Science ®Google Scholar
• Silverman L. B., Gelber R. D., Dalton V. K., et al. Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91–0. Blood, 2001; 97: 1211–1218
   PubMed Web of Science ®Google Scholar
• Vilmer E., Suciu S., Ferster A., et al. Long-term results of three randomized trials (58831, 58832, 58881) in childhood acute lymphoblastic leukemia: a CLCG-EORTC report. Leukemia, 2000; 14: 2257–2266
   PubMed Web of Science ®Google Scholar
• Gustafsson G., Schmiegelow K., Forestier E., et al. Improving outcome through two decades in childhood ALL in the Nordic countries: the impact of high-dose methotrexate in the reduction of central nervous system irradiation. Leukemia, 2000; 14: 2267–2275
   PubMed Web of Science ®Google Scholar
• Uckun F. M., Sensel M. G., Sun L., Steinherz P. G., Trigg M. E., Heerema N. A., Sather H. N., Reaman G. H., Gaynon P. S. Biology and treatment of childhood T-lineage acute lymphoblastic leukemia. Blood 1998; 91: 735–746
   PubMed Web of Science ®Google Scholar
• Larson R. A. The U. S. trials in adult acute lymphoblastic leukemia. Ann. Hematol. 2004; 83: S127–S128, (Suppl 1)
   PubMed Web of Science ®Google Scholar
• Annino L., Vegna M. L., Camera A., et al. Treatment of adult acute lymphoblastic leukemia (ALL): long-term follow-up of the GIMEMA ALL 0288 randomized study. Blood, 2002; 99: 863–871
   PubMed Web of Science ®Google Scholar
• Goekbuget N., Arnold R., Buechner T., et al. Intensification of induction and consolidation improves only subgroups of adult ALL: analysis of 1200 patients in GMALL study 05/93. Blood 2001; 98: 802
   Web of Science ®Google Scholar
• Kantarjianm H., Thomas D., O'Brien S., et al. Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia. Cancer 2004; 101: 2788–2801
   PubMed Web of Science ®Google Scholar
• Thomas X., Boiron J. M., Huguet F., et al. Outcome of treatment in adults with acute lymphoblastic leukemia: analysis of the LALA-94 trial. J. Clin. Oncol. 2004; 22: 4075–4086
   PubMed Web of Science ®Google Scholar
• Abbott B. L. Chronic lymphocytic leukemia: recent advances in diagnosis and treatment. Oncologist 2006; 11: 21–30
   PubMed Web of Science ®Google Scholar
• Tolomeo M., Simoni D. Drug resistance and apoptosis in cancer treatment: development of new apoptosis-inducing agents active in drug resistant malignancies. Curr. Med. Chem. Anti-Cancer Agents 2002; 2: 387–401
   PubMedGoogle Scholar
• Gentile M., Mauro F. R., Guarini A., Foa R. New developments in the diagnosis, prognosis and treatment of chronic lymphocytic leukemia. Curr. Opin. Oncol. 2005; 17: 597–604
   PubMed Web of Science ®Google Scholar
• Krishnan B., Matutes E., Dearden C. Prolymphocytic leukemias. Semin. Oncol. 2006; 33: 257–263
   PubMed Web of Science ®Google Scholar
• Byrd J. C., Lin T. S., Grever M. R. Treatment of relapsed chronic lymphocytic leukemia: old and new therapies. Semin. Oncol. 2006; 33: 210–219
   PubMed Web of Science ®Google Scholar
• Abbott B. L. Chronic lymphocytic leukemia: recent advances in diagnosis and treatment. Oncologist 2006; 11: 21–30
   PubMed Web of Science ®Google Scholar
• Tsimberidou A. M., Keating M. J. Richter's transformation in chronic lymphocytic leukemia. Semin. Oncol. 2006; 33: 250–256
   PubMed Web of Science ®Google Scholar
• Wierda W. G., O'Brien S. M. Initial therapy for patients with chronic lymphocytic leukemia. Semin. Oncol. 2006; 33: 202–209
   PubMed Web of Science ®Google Scholar
• Uckun F. M. Treating Chronic Leukemias. Minnesota Physician 2002; 16: 14
   Google Scholar
• Evrard S., Gaussem P., Helley D., Darnige L. [Prognostic factors in chronic lymphocytic leukaemia: contribution of recent biological markers]. Ann. Biol. Clin. (Paris) 2005; 63: 589–597
   PubMed Web of Science ®Google Scholar
• Molica S., Vitelli G., Levato D., Giannarelli D., Vacca A., Cuneo A., Ribatti D., Digiesi G. Serum angiogenin is not elevated in patients with early B-cell chronic lymphocytic leukemia but is prognostic factor for disease progression. Eur. J. Haematol. 2004; 73: 36–42
   PubMed Web of Science ®Google Scholar
• Korte W., Cogliatti S. [Chronic lymphocytic leukemia–the old and the new]. Ther. Umsch. 2004; 61: 151–156
   PubMedGoogle Scholar
• Pangalis G. A., Vassilakopoulos T. P., Dimopoulou M. N., Siakantaris M. P., Kontopidou F. N., Angelopoulou M. K. B-chronic lymphocytic leukemia: practical aspects. Hematol. Oncol. 2002; 20: 103–146
   PubMed Web of Science ®Google Scholar
• Faria de J. R., de Oliveira J. S., Delbone de Faria R. M., Silva M. R., Goihman S., Yamamoto M., et al. Prognosis related to staging systems for chronic lymphocytic leukemia. Sao Paulo Med. J., 2000; 118: 83–88
   PubMedGoogle Scholar
• Moreno C., Villamor N., Colomer D., Esteve J., Martino R., Nomdedeu J., Bosch F., Guillermo Lopez-A., Campo E., Sierra J., et al. Allogeneic stem-cell transplantation may overcome the adverse prognosis of unmutated VH gene in patients with chronic lymphocytic leukemia. J. Clin. Oncol., 2005; 23: 3433–3438
   PubMed Web of Science ®Google Scholar
• Lin K., Glenn M. A., Harris R. J., Duckworth A. D., Dennett S., Cawley J. C., Zuzel M., Slupsky J. R. c-Abl expression in chronic lymphocytic leukemia cells: clinical and therapeutic implications. Cancer Res. 2006; 66: 7801–7809
   PubMed Web of Science ®Google Scholar
• Rodriguez A., Martinez N., Camacho F. I., Ruiz-Ballesteros E., Algara P., Garcia J. F., Menarguez J., Alvaro T., Fresno M. F., Solano F., et al. Variability in the degree of expression of phosphorylated IkappaBalpha in chronic lymphocytic leukemia cases with nodal involvement. Clin. Cancer Res., 2004; 10: 6796–6806
   PubMed Web of Science ®Google Scholar
• American Cancer Society. What are the key statistics about non-hodgkin's lymphoma, www.cancer.org Available at
   Google Scholar
• Vassilev A. O., Tibbles H. E., DuMez D., Venkatachalam T. K., Uckun F. M. Targeting JAK3 and BTK tyrosine kinases with rationally-designed inhibitors. Curr. Drug Targets 2006; 3: 327–343
   Google Scholar
• Tibes R., Trent J., Kurzrock R. Tyrosine kinase inhibitors and the dawn of molecular cancer therapeutics. Annu. Rev. Pharmacol. Toxicol. 2005; 45: 357
   PubMed Web of Science ®Google Scholar
• Chalandon Y., Schwaller J. Targeting mutated protein tyrosine kinases and their signaling pathways in hematologic malignancies. Haematologica 2005; 90: 949
   PubMed Web of Science ®Google Scholar
• Traxler P. Tyrosine kinases as targets in cancer therapy—successes and failures. Expert Opin Ther Targets 2003; 7: 215
   PubMed Web of Science ®Google Scholar
• Krause D. S., Van R. A. Etten. Tyrosine kinases as targets for cancer therapy. N. Engl. J. Med. 2005; 353: 172
   PubMed Web of Science ®Google Scholar
• Uckun F. M., Tibbles H. E., Vassilev A. O. Bruton's tyrosine kinase as a new therapeutic target. Curr. Med. Chem. 2007, (In press)
   Google Scholar
• Schwartzberg P. L., Finkelstein L. D., Readinger J. A. TEC-family kinases: regulators of T-helper-cell differentiation. Nat. Rev. Immunol. 2005; 5: 284
   PubMed Web of Science ®Google Scholar
• Vassilev A. O., Uckun F. M. Therapeutic potential of inhibiting Bruton's tyrosine kinase, (BTK). Curr. Pharm. Des. 2004; 10: 1757
   PubMed Web of Science ®Google Scholar
• Kurosaki T., Tsukada S. BLNK: connecting Syk and Btk to calcium signals. Immunity 2000; 12: 1
   PubMed Web of Science ®Google Scholar
• Tsukada S., Simon M. I., Witte O. N., et al. Binding of beta gamma subunits of heterotrimeric G proteins to the PH domain of Bruton tyrosine kinase. Proc. Natl. Acad. Sci. USA. 1994; 91: 11256
   PubMed Web of Science ®Google Scholar
• Lindvall J. M., Blomberg K. E., Valiaho J., et al. Bruton's tyrosine kinase: cell biology, sequence conservation, mutation spectrum, siRNA modifications, and expression profiling. Immunol. Rev. 2005; 203: 200
   PubMed Web of Science ®Google Scholar
• Vassilev A., Ozer Z., Navara C., et al. Bruton's tyrosine kinase as an inhibitor of the Fas/CD95 death-inducing signaling complex. J. Biol. Chem. 1999; 274: 1646
   PubMed Web of Science ®Google Scholar
• Uckun F. M. Bruton's tyrosine kinase (BTK) as a dual-function regulator of apoptosis. Biochem. Pharmacol. 1998; 56: 683
   PubMed Web of Science ®Google Scholar
• Uckun F. M., Waddick K. G., Mahajan S., et al. BTK as a mediator of radiation-induced apoptosis in DT-40 lymphoma B cells. Science 1996; 273: 1096
   PubMed Web of Science ®Google Scholar
• Bajpai U. D., Zhang K., Teutsch M., et al. Bruton's tyrosine kinase links the B cell receptor to nuclear factor kappaB activation. J. Exp. Med. 2000; 191: 1735
   PubMed Web of Science ®Google Scholar
• Kawakami Y., Miura T., Bissonnette R., et al. Bruton's tyrosine kinase regulates apoptosis and JNK/SAPK kinase activity. Proc. Natl. Acad. Sci. USA. 1997; 94: 3938
   PubMed Web of Science ®Google Scholar
• Mahajan S., Vassilev A., Sun N., et al. Transcription factor STAT5A is a substrate of Bruton's tyrosine kinase in B cells. J. Biol. Chem. 2001; 276: 31216
   PubMed Web of Science ®Google Scholar
• Varnai P., Rother K. I., Balla T. Phosphatidylinositol 3-kinase-dependent membrane association of the Bruton's tyrosine kinase pleckstrin homology domain visualized in single living cells. J. Biol. Chem. 1999; 274: 10983
   PubMed Web of Science ®Google Scholar
• Petro J. B., Khan W. N. Phospholipase C-gamma 2 couples Bruton's tyrosine kinase to the NF-kappaB signaling pathway in B lymphocytes. J. Biol. Chem. 2001; 276: 1715
   PubMed Web of Science ®Google Scholar
• Qiu Y., Kung H. J. Signaling network of the Btk family kinases. Oncogene. 2000; 19: 5651
   PubMed Web of Science ®Google Scholar
• Rajaiya J., Nixon J. C., Ayers N., Desgranges Z. P., Roy A. L., Webb C. F. Induction of immunoglobulin heavy-chain transcription through the transcription factor Bright requires TFII-I. Mol. Cell. Biol. 2006; 26: 4758–4768
   PubMed Web of Science ®Google Scholar
• Brunner C., Wirth T. Btk expression is controlled by Oct and BOB.1/OBF.1. Nucleic Acids Res. 2006; 34: 1807–1815
   PubMed Web of Science ®Google Scholar
• Tahvanainen J., Pykalainen M., Kallonen T., Lahteenmaki H., Rasool O., Lahesmaa R. Enrichment of nucleofected primary human CD4+ T cells: a novel and efficient method for studying gene function and role in human primary T helper cell differentiation. J. Immunol. Methods 2006; 310: 30–39
   PubMed Web of Science ®Google Scholar
• Popescu F. D. Antisense-and RNA interference-based therapeutic strategies in allergy. J. Cell. Mol. Med. 2005; 9: 840–853
   PubMed Web of Science ®Google Scholar
• Filen J. J., Nyman T. A., Korhonen J., Goodlett D. R., Lahesmaa R. Characterization of microsomal fraction proteome in human lymphoblasts reveals the down-regulation of galectin-1 by interleukin-12. Proteomics 2005; 5: 4719–4732
   PubMed Web of Science ®Google Scholar
• Iwaki S., Tkaczyk C., Satterthwaite A. B., Halcomb K., Beaven M. A., Metcalfe D. D., Gilfillan A. M. Btk plays a crucial role in the amplification of Fc epsilonRI-mediated mast cell activation by kit. J. Biol. Chem. 2005; 280: 40261–40270
   PubMed Web of Science ®Google Scholar
• Lindvall J. M., Blomberg K. E., Wennborg A., Smith C. I. Differential expression and molecular characterisation of Lmo7, Myo1e, Sash1, and Mcoln2 genes in Btk-defective B-cells. Cell Immunol. 2005; 235: 46–55
   PubMed Web of Science ®Google Scholar
• Doyle S. L., Jefferies C. A., O'Neill L. A. Bruton's tyrosine kinase is involved in p65-mediated transactivation and phosphorylation of p65 on serine 536 during NFkappaB activation by lipopolysaccharide. J. Biol. Chem., 2005; 280: 23496–23501
   PubMed Web of Science ®Google Scholar
• Rajaiya J., Hatfield M., Nixon J. C., Rawlings D. J., Webb C. F. Bruton's tyrosine kinase regulates immunoglobulin promoter activation in association with the transcription factor Bright. Mol. Cell Biol. 2005; 25: 2073–2084
   PubMed Web of Science ®Google Scholar
• Pykalainen M., Kinos R., Valkonen S., Rydman P., Kilpelainen M., Laitinen L. A., Karjalainen J., Nieminen M., Hurme M., Kere J., Laitinen T., Lahesmaa R. Association analysis of common variants of STAT6, GATA3, and STAT4 to asthma and high serum IgE phenotypes. J. Allergy Clin. Immunol. 2005; 115: 80–87
   PubMed Web of Science ®Google Scholar
• Takatsu K. [Role of interleukin-5 in immune regulation and inflammation]. Nippon Rinsho 2004; 62: 1941–1951
   PubMedGoogle Scholar
• Ruiz-Ballesteros E., Mollejo M., Rodriguez A., Camacho F. I., Algara P., Martinez N., Pollan Sanchez-A. Aguilera M., Menarguez J., Campo E., et al. Splenic marginal zone lymphoma: proposal of new diagnostic and prognostic markers identified after tissue and cDNA microarray analysis. Blood, 2005; 106: 1831–1838
   PubMed Web of Science ®Google Scholar
• Kaku H., Horikawa K., Obata Y., Kato I., Okamoto H., Sakaguchi N., Gerondakis S., Takatsu K. NF-kappaB is required for CD38-mediated induction of C(gamma)1 germline transcripts in murine B lymphocytes. Int. Immunol. 2002; 14: 1055–1064
   PubMed Web of Science ®Google Scholar
• Mohamed A. J., Vargas L., Nore B. F., et al. Nucleocytoplasmic shuttling of Bruton's tyrosine kinase. J. Biol. Chem. 2000; 275: 40614
   PubMed Web of Science ®Google Scholar
• Kim R. Recent advances in understanding the cell death pathways activated by anticancer therapy. Cancer 2005; 103: 1551–1560
   PubMed Web of Science ®Google Scholar
• Fulda S., Debatin K. M. Targeting apoptosis pathways in cancer therapy. Curr Cancer Drug Targets 2004; 4: 569–576
   PubMed Web of Science ®Google Scholar
• Ghobrial I. M., Witzig T. E., Adjei A. A. Targeting apoptosis pathways in cancer therapy. CA Cancer J. Clin. 2005; 55: 178–194
   PubMed Web of Science ®Google Scholar
• Uckun F. M., Pallisgaard N., Hokland P., Navara C., Narla R., Gaynon P. S., Sather H., Heerema N. Expression of TEL-AML1 fusion transcripts and response to induction therapy in standard risk acute lymphoblastic leukemia. Leuk Lymphoma. 2001; 42(1–2)41–56
   PubMed Web of Science ®Google Scholar
• Narla R., Navara C., Sarquis M., Uckun F. M. Chemosensitivity of TEL-AML1 fusion transcript positive acute lymphoblastic leukemia cells. Leuk Lymphoma. 2001; 41(5–6)615–623
   PubMed Web of Science ®Google Scholar
• Holleman A., et al. Gene-expression patterns in drug-resistant acute lymphoblastic leukemia cells and response to treatment. N. Engl. J. Med. 2004; 351: 533–542
   PubMed Web of Science ®Google Scholar
• Wuchter C., et al. In vitro susceptibility to dexamethasone-and doxorubicin-induced apoptotic cell death in context of maturation stage, responsiveness to interleukin 7, and early cytoreduction in vivo in childhood T-cell acute lymphoblastic leukemia. Blood 2002; 99: 4109–4115
   PubMed Web of Science ®Google Scholar
• Tibbles H., Vassilev A., Uckun F. M. A dual function anti-leukemic agent with anti-thrombotic activity. Leuk Lymphoma 2002; 43: 1121–1127
   PubMed Web of Science ®Google Scholar
• Kaufmann S. H., Vaux D. L. Alterations in the apoptotic machinery and their potential role in anticancer drug resistance. Oncogene 2003; 22: 7414–7430
   PubMed Web of Science ®Google Scholar
• Feldhahn N., Klein F., Mooster J. L., et al. Mimicry of a constitutively active pre-B cell receptor in acute lymphoblastic leukemia cells. J. Exp. Med. 2005; 201: 1837
   PubMed Web of Science ®Google Scholar
• Mao C., Zhou M., Uckun F. M. Crystal structure of Bruton's tyrosine kinase domain suggests a novel pathway for activation and provides insights into the molecular basis of X-linked agammaglobulinemia. J. Biol. Chem. 2001; 276: 41435
   PubMed Web of Science ®Google Scholar
• Mahajan S., Ghosh S., Sudbeck E. A., et al. Rational design and synthesis of a novel anti-leukemic agent targeting Bruton's tyrosine kinase (BTK), LFM-A13 [alpha-cyano-beta-hydroxy-beta-methyl-N-(2, 5-dibromophenyl)propenamide]. J. Biol. Chem. 1999; 274: 9587
   PubMed Web of Science ®Google Scholar
• Uckun F. M., Zheng Y., Cetkovic-Cvrlje M., et al. In vivo pharmacokinetic features, toxicity profile, and chemosensitizing activity of alpha-cyano-beta-hydroxy-beta-methyl-N-(2,5-dibromophenyl)propenamide (LFM-A13), a novel antileukemic agent targeting Bruton's tyrosine kinase. Clin. Cancer Res. 2002; 8: 1224
   PubMed Web of Science ®Google Scholar
• Kim Y. J., Sekiya F., Poulin B., Bae Y. S., Rhee S. G. Mechanism of B-cell receptor-induced phosphorylation and activation of phospholipase C-gamma2. Mol. Cell. Biol. 2004; 24: 9986–9999
   PubMed Web of Science ®Google Scholar
• Heinonen J. E., Smith C. I., Nore B. F. Silencing of Bruton's tyrosine kinase (Btk) using short interfering RNA duplexes (siRNA). FEBS Lett. 2002; 527: 274–278
   PubMed Web of Science ®Google Scholar
• Glassford J., Soeiro I., Skarell S. M., Banerji L., Holman M., Klaus G. G., Kadowaki T., Koyasu S., Lam E. W. BCR targets cyclin D2 via Btk and the p85alpha subunit of PI3-K to induce cell cycle progression in primary mouse B cells. Oncogene 2003; 22: 2248–2259
   PubMed Web of Science ®Google Scholar
• Feldhahn N., Rio P., Soh B. N., Liedtke S., Sprangers M., Klein F., Wernet P., Jumaa H., Hofmann W. K., Hanenberg H., et al. Deficiency of Bruton's tyrosine kinase in B cell precursor leukemia cells. Proc. Natl. Acad. Sci. USA 2005; 102: 13266–13271
   PubMed Web of Science ®Google Scholar
• Fernandes M. J., Lachance G., Pare Rollet-E. Labelle G., Naccache P. H. Signaling through CD16b in human neutrophils involves the Tec family of tyrosine kinases. J. Leukoc. Biol., 2005; 78: 524–532
   PubMed Web of Science ®Google Scholar
• Uckun F. M., Dibirdik I., Qazi S., Vassilev A., Ma H., Mao C., Benyumov A., Emami K. H. In vitro and in vivo anti-breast cancer activity of LFM-A13, a potent inhibitor of polo-like kinase (PLK). Bioorg. Med. Chem. 2006
   Google Scholar
• Tibbles H. E., Samuel P., Erbeck D., Mahajan S., Uckun F. M. In vivo toxicity and antithrombotic profile of the oral formulation of the antileukemic agent, LFM-A13-F. Arzneimittelforschung/Drug Res. 2004; 54(6)330–339
   PubMed Web of Science ®Google Scholar
• Uckun F. M., Tibbles H., Venkatachalam T. K., DuMez D., Erbeck D. Preclinical toxicity and pharmacokinetics of the BTK-targeting antileukemic drug candidate, α-cyano-β-hydroxy-β-methyl-N-(2,5-dibromophenyl) propenamide (LFM-A13). Arzneimittelforschung. 2007; 57(1)31–46
   PubMed Web of Science ®Google Scholar
• “BTK inhibitors and methods for their identification and use.”. US Patent No. 6365626, April 2, 2002
   Google Scholar
• Conley M. E., Broides A., Hernandez-Trujillo V., Howard V., Kanegane H., Miyawaki T., Shurtleff S. A. Genetic analysis of patients with defects in early B-cell development. Immunol. Rev. 2005; 203: 216–234
   PubMed Web of Science ®Google Scholar
• Lindvall J. M., Blomberg K. E., Valiaho J., Vargas L., Heinonen J. E., Berglof A., Mohamed A. J., Nore B. F., Vihinen M., Smith C. I. Bruton's tyrosine kinase: cell biology, sequence conservation, mutation spectrum, siRNA modifications, and expression profiling. Immunol. Rev. 2005; 203: 200–215
   PubMed Web of Science ®Google Scholar
• Verbruggen G., De Backer S., Deforce D., Demetter P., Cuvelier C., Veys E., Elewaut D. X linked agammaglobulinaemia and rheumatoid arthritis. Ann. Rheum. Dis. 2005; 64: 1075–1078
   PubMed Web of Science ®Google Scholar
• Liljeroos M., Vuolteenaho R., Morath S., Hartung T., Hallman M., Ojaniemi M. Bruton's tyrosine kinase together with PI 3-kinase are part of Toll-like receptor 2 multiprotein complex and mediate LTA induced Toll-like receptor 2 responses in macrophages. Cell. Signal. 2007; 19: 625–633
   PubMed Web of Science ®Google Scholar
• Horwood N. J., Page T. H., McDaid J. P., Palmer C. D., Campbell J., Mahon T., Brennan F. M., Webster D., Foxwell B. M. Bruton's tyrosine kinase is required for TLR2 and TLR4-induced TNF, but not IL-6, production. J. Immunol. 2006; 176: 3635–3641
   PubMed Web of Science ®Google Scholar
• Horwood N. J., Mahon T., McDaid J. P., Campbell J., Mano H., Brennan F. M., Webster D., Foxwell B. M. Bruton's tyrosine kinase is required for lipopolysaccharide-induced tumor necrosis factor α production. J. Exp. Med. 2003; 197: 1603–1611
   PubMed Web of Science ®Google Scholar
• Gilbert C., Levasseur S., Desaulniers P., Dusseault A. A., Thibault N., Bourgoin S. G., Naccache P. H. Chemotactic factor-induced recruitment and activation of Tec family kinases in human neutrophils. II. Effects of LFM-A13, a specific Btk inhibitor. J. Immunol. 2003; 170: 5235–5243
   PubMed Web of Science ®Google Scholar
• Fernandes M. J., Lachance G., Pare G., Rollet-Labelle E., Naccache P. H. Signaling through CD16b in human neutrophils involves the Tec family of tyrosine kinases. J. Leukoc. Biol. 2005; 78: 524–532
   PubMed Web of Science ®Google Scholar
• Matsuo K., Hotokezaka H., Ohara N., Fujimura Y., Yoshimura A., Okada Y., Hara Y., Yoshida N., Nakayama K. Analysis of amphotericin B-induced cell signaling with chemical inhibitors of signaling molecules. Microbiol. Immunol. 2006; 50: 337–347
   PubMed Web of Science ®Google Scholar
• Olsson S., Sundler R. Different roles for non-receptor tyrosine kinases in arachidonate release induced by zymosan and Staphylococcus aureus in macrophages. J. Inflamm. (Lond) 2006; 3: 8
   PubMedGoogle Scholar
• http://www.medicinenet.com/asthma/page2.htm MedicineNet.com Asthma information. Available at
   Google Scholar
• American Lung Association. Epidemiology & Statistics Unit. Trends in Asthma Morbidity and Mortality. 2005, http://www.lungusa.org Available at
   Google Scholar
• Heinonen J. E., Smith C. I., Nore B. F. Silencing of Bruton's tyrosine kinase (Btk) using short interfering RNA duplexes (siRNA). FEBS Lett. 2002; 527: 274–278
   PubMed Web of Science ®Google Scholar
• Thomas E. D. Stem cell transplantation: past, present and future. Arch. Immunol. Ther. Exp. (Warsz) 1997; 45: 1–5
   PubMedGoogle Scholar
• O'Reilly R. J., Papadopoulos E. B. Allogeneic Transplantation., 4th ed. William and Wilkins, Baltimore 1997
   Google Scholar
• Trigg M. E. Bone marrow transplantation for treatment of leukemia in children. Pediatr Clin. North Am. 1988; 35: 933–948
   PubMed Web of Science ®Google Scholar
• Ramsay N. K., Kersey J. H. Indications for marrow transplantation in acute lymphoblastic leukemia. Blood 1990; 75: 815–818
   PubMed Web of Science ®Google Scholar
• Butturini A., Gale R. P. Allogeneic bone marrow transplantation for leukemia. Curr. Opin. Hematol. 1994; 1: 402–405
   PubMedGoogle Scholar
• Henslee-Downey P. J. Mismatched bone marrow transplantation. Curr. Opin. Oncol. 1995; 7: 115–121
   PubMedGoogle Scholar
• Leelasiri A., Greer J. P., Stein R. S., Goodman S., Brandt S. A., Edwards J. R., Wolff S. N. Graft-versus-host-disease prophylaxis for matched unrelated donor bone marrow transplantation: comparison between cyclosporine-methotrexate and cyclosporine-methotrexate-methylprednisolone. Bone Marrow Transplant 1995; 15: 401–405
   PubMed Web of Science ®Google Scholar
• Porter D. L., Jr., Collins R. H., Shpilberg O., Drobyski W. R., Connors J. M., Sproles A., Antin J. H. Long-term follow-up of patients who achieved complete remission after donor leukocyte infusions. Biol. Blood Marrow Transplant., 1999; 5: 253–261
   PubMedGoogle Scholar
• Orchard P. J., Miller J. S., McGlennen R., Davies S. M., Ramsay N. K. Graft-versus-leukemia is sufficient to induce remission in juvenile myelomonocytic leukemia. Bone Marrow Transplant 1998; 22: 201–3
   PubMed Web of Science ®Google Scholar
• Slavin S., Nagler A., Shapira M., Panigrahi S., Samuel S., Or A. Non-myeloablative allogeneic stem cell transplantation focusing on immunotherapy of life-threatening malignant and non-malignant diseases. Crit. Rev. Oncol. Hematol. 2001; 39: 25–29
   PubMed Web of Science ®Google Scholar
• Champlin R. Nonmyeloablative chemotherapy with allogeneic hematopoietic transplantation as adoptive immunotherapy for malignancies. Hemotology. ASH Education Program Book 1999; 413–416
   Google Scholar
• Spitzer T. R., McAfee S., Sackstein R., Colby C., Toh H. C., Multani P., Saidman S., Weyouth D. W., Preffer F., Poliquin C., Foley A., et al. Intentional induction of mixed chimerism and achievement of antitumor responses after nonmyeloablative conditioning therapy and HLA-matched donor bone marrow transplantation for refractory hematologic malignancies. Biol. Blood Marrow Transplant, 2000; 6: 309–320
   PubMed Web of Science ®Google Scholar
• Martin P. J., Hansen J. A., Torok-Storb B., Durnam D., Przepiorka D., O'Quigley J., Sanders J., Sullivan K. M., Witherspoon R. P., Deeg H. J., et al. Graft failure in patients receiving T-cell depleted HLA-identical allogeneic marrow transplants. Bone Marrow Transplant, 1988; 3: 445–456
   PubMed Web of Science ®Google Scholar
• Marmont A. M., Horowitz M., Gale R., Sobocinski K., Ash R., van Bekkum D., Champlin R., Dicke K., Goldman J., Good R., Herzig R., Hong R., et al. T cell depletion of HLA-identical transplants in leukemia. Blood, 1991; 78: 2120–2130
   PubMed Web of Science ®Google Scholar
• Poynton C. T cell depletion in bone marrow transplantation. Bone Marrow Transplant 1988; 3: 265–279
   PubMed Web of Science ®Google Scholar
• Berenson R. J., Shpall E. J., Auditore-Hargreaves K., Heimfeld S., Jacobs C., Krieger M. S. Transplantation of CD34+ hematopoietic progenitor cells. Cancer Invest, 1996; 14: 589–596
   PubMed Web of Science ®Google Scholar
• O'Reilly R. J. Allogeneic bone marrow transplantation: current status and future directions. Blood 1983; 62: 941–964
   PubMed Web of Science ®Google Scholar
• Apperly J. F., Jones L., Hale G., Waldmann H., Hows J., Rombos Y., Tsatalas C., Marcus R. E., Goolden A. W., Gordon-Smith E. C., et al. Bone marrow transplantation for patients with chronic myeloid leukemia: T-cell depletion with Campath-1 reduces the incidence of graft-versus-host disease but may increase the risk of leukemic relapse. Bone Marrow Transplant, 1986; 1: 53–60
   PubMed Web of Science ®Google Scholar
• Cetkovic-Cvrlje M., Uckun F. M. Dual targeting of Bruton's tyrosine kinase and Janus kinase 3 with rationally designed inhibitors prevents graft-versus-host disease (GVHD) in a murine allogeneic bone marrow transplantation model. Br. J. Haematol. 2004; 126: 821–827
   PubMed Web of Science ®Google Scholar
• Sierko E., Wojtukiewicz M. Z. Platelets and angiogenesis in malignancy. Semin Thromb. Hemost. 2004; 30: 95–108
   PubMed Web of Science ®Google Scholar
• Zacharski L. R., Prandoni P., Monreal M. Warfarin versus low-molecular-weight heparin therapy in cancer patients. Oncologist 2005; 10: 72–79
   PubMed Web of Science ®Google Scholar
• Ameriso S. F. [The treatment of cerebrovascular disorders with anticoagulants and platelet aggregation inhibitors]. Rev. Neurol., 1999; 29: 1285–1290
   PubMed Web of Science ®Google Scholar
• Michiels J. J. Aspirin and platelet-lowering agents for the prevention of vascular complications in essential thrombocythemia. Clin. Appl. Thromb. Hemost. 1999; 5: 247–251
   PubMed Web of Science ®Google Scholar
• Barsness G. W., Buller C., Ohman E. M., Schechter E., Pucillo A., Taylor M. A., Miller M. J., Reiner J. S., Churchill D., Chandler A. B., et al. Reduced thrombus burden with abciximab delivered locally before percutaneous intervention in saphenous vein grafts. Am. Heart J., 2000; 139: 824–829
   PubMed Web of Science ®Google Scholar
• Foussas S., Alexopoulos D., Stefanadis C., Olympios C., Voudris V., Hatzimiltiadis S., Sionis D., Vavouranakis E., Vrahatis A., Fakiolas C., et al. Antiplatelet is superior to anticoagulant treatment after coronary stenting: fewer coronary and other events within 30 days after stenting. Angiology, 2000; 51: 289–294
   PubMed Web of Science ®Google Scholar
• Fredrickson B. J., Turner N. A., Kleiman N. S., Graziadei N., Maresh K., Mascelli M. A., Effron M. B., McIntire L. V. Effects of abciximab, ticlopidine, and combined Abciximab/Ticlopidine therapy on platelet and leukocyte function in patients undergoing coronary angioplasty. Circulation 2000; 101: 1122–1129
   PubMed Web of Science ®Google Scholar
• Guilmot J. L., Diot E., Gruel Y. [Contribution of platelet aggregation inhibitors in the prevention of complications of atherothrombosis]. Presse Med. 2000; 29: 709–716
   PubMed Web of Science ®Google Scholar
• Roe M. T., Sapp S. K., Lincoff A. M. Glycoprotein IIb/IIIa inhibitors in acute coronary syndromes. Cleve Clin. J. Med. 2000; 67: 131–140
   PubMed Web of Science ®Google Scholar
• Sukavaneshvar S., Solen K. A., Mohammad S. F. An in-vitro model to study device-induced thrombosis and embolism: evaluation of the efficacy of tirofiban, aspirin, and dipyridamole. Thromb Haemost 2000; 83: 322–326
   PubMed Web of Science ®Google Scholar
• Segal J. B., McNamara R. L., Miller M. R., Kim N., Goodman S. N., Powe N. R., Robinson K. A., Bass E. B. Prevention of thromboembolism in atrial fibrillation. A meta-analysis of trials of anticoagulants and antiplatelet drugs. J. Gen. Intern. Med. 2000; 15: 56–67
   PubMed Web of Science ®Google Scholar
• Sugidachi A., Asai F., Ogawa T., Inoue T., Koike H. The in vivo pharmacological profile of CS-747, a novel antiplatelet agent with platelet ADP receptor antagonist properties. Br. J. Pharmacol. 2000; 129: 1439–1446
   PubMed Web of Science ®Google Scholar
• Verstraete M. Synthetic inhibitors of platelet glycoprotein IIb/IIIa in clinical development. Circulation 2000; 101: E76–E80
   PubMed Web of Science ®Google Scholar
• Yuk D. Y., Lee H. Y., Ryu C. K., Hong J. T., Kang W. S., Yoo H. S., Yun Y. P. Studies on the antithrombotic and antiplatelet activities of NQ304, a newly synthesized naphthoquinone derivative. Arzneimittelforschung 2000; 50: 254–259
   PubMed Web of Science ®Google Scholar
• Tibbles H. E., Samuel P., Erbeck D., Mahajan S., Uckun F. M. In vivo toxicity and antithrombotic profile of the oral formulation of the antileukemic agent, LFM-A13-F. Arzneimittelforschung 2004; 54: 330–339
   PubMed Web of Science ®Google Scholar
• Gibbins J. M., Okuma M., Farndale R., Barnes M., Watson S. P. Glycoprotein VI is the collagen receptor in platelets which underlies tyrosine phosphorylation of the Fc receptor gamma-chain. FEBS Lett. 1997; 413: 255–259
   PubMed Web of Science ®Google Scholar
• Moroi M., Jung S. M. Platelet receptors for collagen. Thromb Haemost 1997; 78: 439–444
   PubMed Web of Science ®Google Scholar
• Tsuji M., Ezumi Y., Arai M., Takayama H. A novel association of Fc receptor gamma-chain with glycoprotein VI and their co-expression as a collagen receptor in human platelets. J. Biol. Chem. 1997; 272: 23528–23531
   PubMed Web of Science ®Google Scholar
• Quek L. S., Bolen J., Watson S. P. A role for Bruton's tyrosine kinase (Btk) in platelet activation by collagen. Curr. Biol. 1998; 8: 1137–1140
   PubMed Web of Science ®Google Scholar
• Uckun F. M., Vassilev A. O., Bartell S., Zheng Y., Mahajan S., Tibbles H. E. The anti-leukemic bruton's tyrosine kinase inhibitor LFM-A13 prevents fatal thromboembolism. Leukemia Lymphoma 2003; 44: 1569–1577
   PubMed Web of Science ®Google Scholar
• Takaya N., Katoh Y., Iwabuchi K., Hayashi I., Konishi H., Itoh S., Okumura K., Ra C., Nagaoka I., Daida H. Platelets activated by collagen through the immunoreceptor tyrosine-based activation motif in the Fc receptor gamma-chain play a pivotal role in the development of myocardial ischemia-reperfusion injury. J. Mol. Cell. Cardiol. 2005; 39: 856–864
   PubMed Web of Science ®Google Scholar
• Wymann M. P., Pirola L. Structure and function of phosphoinositide 3-kinases. Biochim. Biophys Acta 1998; 1436: 127–150
   PubMed Web of Science ®Google Scholar
• Oda A., Ikeda Y., Ochs H. D., Druker B. J., Ozaki K., Handa M., Ariga T., Sakiyama Y., Witte O. N., Wahl M. I. Rapid tyrosine phosphorylation and activation of Bruton's tyrosine/Tec kinases in platelets induced by collagen binding or CD32 cross-linking. Blood 2000; 95: 1663–1670
   PubMed Web of Science ®Google Scholar
• Gibbins J. M. Platelet adhesion signalling and the regulation of thrombus formation. J. Cell. Sci. 2004; 117: 3415–3425
   PubMed Web of Science ®Google Scholar
• Watson S. Collagen receptor signalling in platelets:extending the role of the ITAM. Immunology Today 1998; 19: 260–264
   PubMedGoogle Scholar
• Guinamard R., Aspenstrom P., Fougereau M., Chavrier P., Guillemot J. C. Tyrosine phosphorylation of the Wiskott-Aldrich syndrome protein by Lyn and Btk is regulated by CDC42. FEBS Lett. 1998; 434: 431–436
   PubMed Web of Science ®Google Scholar
• Snapper S. B., Rosen F. S. The Wiskott-Aldrich syndrome protein (WASP): roles in signaling and cytoskeletal organization. Annu. Rev. Immunol. 1999; 17: 905–929
   PubMed Web of Science ®Google Scholar
• Gross B. S., Wilde J. I., Quek L., Chapel H., Nelson D. L., Watson S. P. Regulation and function of WASp in platelets by the collagen receptor, glycoprotein VI. Blood 1999; 94: 4166–4176
   PubMed Web of Science ®Google Scholar
• Laffargue M., Ragab-Thomas J. M., Ragab A., Tuech J., Missy K., Monnereau L., Blank U., Plantavid M., Payrastre B., Raynal P., et al. Phosphoinositide 3-kinase and integrin signalling are involved in activation of Bruton tyrosine kinase in thrombin-stimulated platelets. FEBS Lett., 1999; 443: 66–70
   PubMed Web of Science ®Google Scholar
• Mukhopadhyay S., Ramars A. S., Dash D. Bruton's tyrosine kinase associates with the actin-based cytoskeleton in activated platelets. J. Cell Biochem. 2001; 81: 659–665
   PubMed Web of Science ®Google Scholar
• Mukhopadhyay S., Ramars A. S., Ochs H. D., Dash D. Bruton's tyrosine kinase is a substrate of calpain in human platelets. FEBS Lett. 2001; 505: 37–41
   PubMed Web of Science ®Google Scholar
• Redondo P. C., Amor Ben-N., Salido G. M., et al. Ca2+-independent activation of Bruton's tyrosine kinase is required for store-mediated Ca2+ entry in human platelets. Cell Signal. 2005; 17: 1011
   PubMed Web of Science ®Google Scholar
• Crosby D., Poole A. W. Interaction of Bruton's tyrosine kinase and protein kinase Ctheta in platelets. Cross-talk between tyrosine and serine/threonine kinases. J. Biol. Chem., 200; 277: 9958–9965
   Google Scholar
• Mitchell L. G. A prospective cohort study determining the prevalence of thrombotic events in children with acute lymphoblastic leukemia and a central venous line who are treated with L-asparaginase. Cancer 2003; 97: 508
   PubMed Web of Science ®Google Scholar
• Gomes M. P., Deitcher S. R. Diagnosis of venous thromboembolic disease in cancer patients. Oncology (Huntingt) 2003; 17: 126
   PubMed Web of Science ®Google Scholar